The federal government’s decision to not provide Novavax’s COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.
The Public Health Agency of Canada said it won’t provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year’s uptake of the vaccine. The health agency said 125,000 Nuvaxovid doses were ordered in 2023, but only 5,529 were administered. This fall, it will only supply provinces and territories with the reformulated Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines.
But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair. Among them is 64-year-old Linda Wilhelm, who has rheumatoid arthritis and takes immunosuppressive drugs for the chronic inflammatory disorder. The Bloomfield-N.
B. resident said she received six mRNA COVID-19 vaccines over a three-year period, but her last shot caused a flare-up in her joints that lasted eight months. Wilhelm said the flare-up was so bad that she even had trouble brushing her hair or chopping vegetables.
After searching for Nuvaxovid at various pharmacies and public health clinics, she said she eventually got a dose in April at a pharmacy in Saint John, N.B., and had no adverse reactions.
“And now, again, I have no options,” Wilhelm said, adding that she’s considering dr.
